@sfishbane on biosimilars in nephrology @NKFCLINICALS #SCM17

@sfishbane #SCM17 on biosimilars in nephrology

@renalmyeloma on renal toxicities of myeloma agents #SCM17

@onconephrology on GN in MGRS #SCM17

Serum free light chain assays best test for diagnosis and treatment follow up. Stick with same assay for consistency #SCM17

Both urinary free light chains and total light chains assays are not a good tests to use #SCM17

Renal range for using serum free light chains #SCM17 via Leung

#SCM17 @onconephrology @renalmyeloma paraproteinemia and the kidney

Winding down #SCM17 starting soon #paraproteinemias and kidney with Nelson Leung , @onconephrology and @renalmyeloma

TAVR #aki #SCM17 @kdjhaveri #VisualAbstract

#SCM17 @hiteshhshah @kdjhaveri @renalmyeloma path education of renal fellows

Two new K buster summary #SCM17

Hemorrhage risk with GFR decline w Coumadin #SCM17

Stroke and ckd and use of warfarin #SCM17 @NKFCLINICALS

View from my room @NKFCLINICALS #Disney #SCM17

Fervenza @MayoClinic #SCM17 on FSGS

Page not found | UNC Kidney Center

Prophylactic Anticoagulation in Patients with Membranous Nephropathy: A Decision Analysis #SCM17 @NKFCLINICALS http://www.unckidneycenter.org/gntools/bleedrisk.html

GN and HSCT #SCM17

#SCM17 @renalmyeloma

HTN comes first @renalmyeloma #SCM17

@renalmyeloma #SCM17

@renalmyeloma using #VisualAbstract in her talk @NKFCLINICALS #SCM17

VOD in HSCT is like a TMA in the liver #SCM17 @renalmyeloma

Risk factors for #aki post HSCT @renalmyeloma #SCM17

#aki incidence HSCT @renalmyeloma #SCM17

@renalmyeloma talking about HSCT induced renal disease #SCM17

Definition of TLS #SCM17

Risk factors for TLS#SCM17

Tumor lysis syndrome #aki mechanism #SCM17

Light chain proximal tubulopathy #SCM17 @NKFCLINICALS